Slide 1: Quantum-Si Corporate Presentation
QUANTUM SI Corporate Presentation @
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations,
Slide 3: Quantum-Si: The Protein Sequencing Company
Quantum-Si: The Protein Sequencing CompanyTM Founded in 2013; NASDAQ (QSI) since June 2021 Experienced team from life sciences leaders including Illumina, PacBio and Ion Torrent Launched the world’s first, next-generation protein sequencing system, Platinum® in December 2022 Over 1,000 owned and lic
Slide 4: The World's First, Next-Generation Protein Sequencer
The World’s First, Next-Generation Protein Sequencer List Price <$100K Automated data analysis Addresses gaps in existing genomics and proteomics research workflows Unmatched Accessibility Kinetic signatures enable single amino acid resolution Single-molecule sensitivity Extensible beyond protein se
Slide 5: Company Key Updates: 2023 Highlights and 2024 Guidance
Company Key Updates 2023 Highlights 2024 Guidance Launched Platinum® in Dec 2022 Successfully executed controlled launch generating $1.1M in revenue Built a world class leadership team Transformed organization from research into commercial phase Enhanced Board of Directors with three new independent
Slide 6: Proteomics Is A Large And Growing Market Opportunity
$75B+ Proteomics Market1 $8B+ Initial Target Market2 Proteomics Is A Large And Growing Market Opportunity Research $20B+ Emerging Clinical $55B+ Identification $3B+ Expression & Quantification $3B+ Proteoforms & PTM’s $1.5B+ 1. SVB Leerink Research, “Proteomics: The Next Frontier in Life Science Too
Slide 7: Proteins Are More Complex And Actionable Than DNA or RNA
Proteins Are More Complex And Actionable Than DNA or RNA 1,000,000+ Proteoforms (Protein) 200,000 Sequences (RNA) 20,000 Genes (DNA) DNA is the blueprint but has limited actionability RNA is more actionable but does not tell the complete story Proteins are extraordinarily diverse and are the real ti
Slide 8: Core Areas Of Proteomics Research Today
Core Areas Of Proteomics Research Today Population Screening Samples: 100’s-1000’s per study Proteins: 1000’s per sample Resolution: Protein Deep Characterization Samples: 10’s-100’s per study Proteins: <50 per sample Resolution: Amino acid; Single-molecule Mass Spec HT Affinity Assays Edman Degrada
Slide 9: Disease Progression Goes Beyond The Protein Level
Disease Progression Goes Beyond The Protein Level Human Proteoform Project https://www.science.org/doi/10.1126/sciadv.abk0734
Slide 10: Deeper Insights With Unprecedented Accessibility
Deeper Insights With Unprecedented Accessibility Mass Spec High Throughput Affinity Based Assays Edman Degradation Western Blots and ELISA Data Richness Accessibility
Slide 11: The Quantum-Si Solution: Prepare, Sequence, Analyze
Library Preparation and Sequencing Kits contain everything you need to digest and functionalize proteins and sequence them on our proprietary semiconductor chip The Quantum-Si Solution Prepare Sequence Analyze Platinum® sequences individual peptides and provides amino acid level resolution Our analy
Slide 12: Sequence Proteins With Next-Generation Protein Sequencing
Sequence Proteins With Next-Generation Protein Sequencing Sequence Prepare Analyze
Slide 13: The Value of Deeper Insights With Next-Generation Protein Sequencing
The Value of Deeper Insights With Next-Generation Protein Sequencing Protein Engineering Antibody Characterization Protein-Protein Interactions Disease Relevance Who Academics, Biopharma, Industry Academics, Biopharma, Industry Academics, Biopharma Academics, Biopharma What Engineering proteins
Slide 14: Platinum Complements And Enhances Current Proteomic and Genomic Workflows
Compliment genomic datasets with protein analysis and uncover direct protein to phenotype relationships Platinum® Complements And Enhances Current Proteomic and Genomic Workflows Next-Gen Sequencing Immunoassays Mass Spectrometry Uncover more than antibodies can with accurate protein identification
Slide 15: Expanding Our Global Commercial Channels And Partnerships
Direct Sales Force Presence Expanding Our Global Commercial Channels And Partnerships 2024 Commercialization Approach Distributor Partner Presence
Slide 16: 2024 Commercial Priorities
2024 Commercial Priorities Accelerate the Purchase Process On-site demos allow customers to evaluate the technology in their own lab Build Our Distribution Network Engage with leading life science tools distributors in select regions – expand network upon proving out model Execute on Full Commercial
Slide 17: Product Enhancements Delivered With The Version 2 Kit And New Software
Product Enhancements Delivered With The Version 2 Kit And New Software Increased proteome coverage with an additional amino acid recognizer Increased output and improved reproducibility Confidently identify proteins with advanced analytical and inference tools Enhanced flexibility with various sampl
Slide 18: Significant Improvement In Product Performance Using The Version 2 Kit
Significant Improvement In Product Performance Using The Version 2 Kit 1K Amino Acids per Chip IL4 IL6 CDNF PDL1 Version 1 Kit Version 2 Kit Increase in Amino Acids Sequenced Increase in Peptides Identified Number of Identified Peptides IL4 IL6 CDNF PDL1 Version 1 Kit Version 2 Kit +4X +2X +3X +5X 6
Slide 19: Version 2 Kit Demonstrates High Reproducibility
Version 2 Kit Demonstrates High Reproducibility Providing Customers More Flexibility In Study Design Performance With Proteins # of Alignments Right Side of Chip # of Alignments Left Side of Chip Single Peptide 10 Peptide Barcodes Performance With Peptides # of Alignments Left Side of Chip (log) IL4
Slide 20: Version 2 Kit Delivers Approximate 3-Fold Reduction In Cost Per 1,000 Amino Acids
Version 2 Kit Delivers An Approximate 3-Fold Reduction In Cost Per 1,000 Amino Acids Amino Acids per Chip (1K) Version 1 Kit Version 2 Kit Cost per 1,000 Amino Acids 528K 154K
Slide 21: Our Innovation Pipeline Is Accelerating
Our Innovation Pipeline Is Accelerating Completed R&D Re-alignment Announce V2 Kit targeting 1Q24 Launch August 2023 V2 Sequencing Kit Launched February 2024 Innovation roadmap continues towards true de-novo sequencing 2026+ Developing new innovations across library prep, sequencing, instruments and
Slide 22: 2024 Corporate Priorities
2024 Corporate Priorities Accelerate commercial adoption Deliver on our innovation roadmap Preserve financial strength Full commercial launch; Direct and distribution model scale up; Revenue of $3.7M - $4.2M V2 Kit Launched in February 24; V3 Kit Launch Targeting 3Q24; Innovation pipeline accelerati
Slide 23: Q&A
QUANTUM SI Q&A